| | Business Summary | | Fountain
Pharmaceuticals
Inc.
was
organized
to
develop
and
commercialize
certain
proprietary
compound
encapsulation
technologies.
The
Company's
base
of
proprietary
technologies
involves
the
creation
of
compound
encapsulation
and
delivery
systems
of
subcellular
size
designated
by
the
Company
as
Solvent
Dilution
MicroCarriers
(SDMC).
These
technologies
are
intended
to
enable
the
Company
to
create
SDMC
formulations
with
defined
biochemical
and
biological
properties,
which
are
designed
to
permit
the
production
of
stable
delivery
systems.
The
SDMCs
are
principally
intended
for
use
in
connection
with
dermal
applications,
solubilization
of
compounds,
parenteral
and
oral
formulations
and
non-pressurized
aerosol
preparations. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Fountain
Pharmaceuticals
was
organized
to
develop
and
commercialize
certain
proprietary
compound
encapsulation
technologies
for
use
in
health
care,
agricultural,
consumer
market
and
veterinary
items.
For
the
six
months
ended
3/31/01,
revenues
fell
33%
to
$382
thousand.
Net
loss
fell
43%
to
$469
thousand.
Revenues
reflect
Spirig
AG
transitioning
its
sunscreen
production
to
a
non-Lyphazome
technology
process.
Lower
loss
reflects
lower
personnel,
travel,
sales
and
marketing
costs. | | More
from
Market Guide: Significant
Developments |
| | Officers | |
| Position | | Joseph Schuchert, Jr., 69 | Chairman | | James Fuchs, 72 | Sec.,
Treasurer |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/f/fphie.ob.gif)